Osimertinib, a third generation TKI that leads to better overall survival compared to other TKIs, has been approved as first-line therapy for patients with metastatic EGFR-driven lung cancer.9 Recently, osimertinib was also approved as adjuvant therapy for early-stage EGFR mutant tumors.10 Outcomes upon osimertinib treatment are variable; thus, the importance of uncovering how co-incident genomic alterations contribute to sensitivity and resistance is of great clinical relevance. This evidence concerns the gene EGFR and lung carcinoma.